Eneboparatide
Eneboparatide (AZP-3601), a 36-amino-acid hybrid analog of PTH and PTH-related peptide (PTHrP) that acts as a parathyroid hormone receptor 1 agonist for chronic hypoparathyroidism (DOI 10.1210/jendso/bvae163.415; DOI 10.1210/jendso/bvad114.562)
Clinical trials are ongoing or recently completed. Final approval has not been granted.
An investigational daily injection being developed for hypoparathyroidism -- a condition where certain glands in the neck do not make enough hormone, leading to low calcium levels, muscle cramps, and other symptoms. A large clinical trial reported positive results in early 2025, with detailed results expected soon.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Across the published human studies in the source set, phase 1 reported only mild-to-moderate adverse events and no serious adverse events (N=104, PMID 40423237), and phase 2 likewise reported no serious adverse events (N=28, PMID 38449442). The phase 3 CALYPSO press release stated eneboparatide was well tolerated at 24 weeks (AstraZeneca press release March 2025, ). Individual adverse event types and their frequencies are not itemized in available abstracts or publications.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-6]